These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 19171862)

  • 21. Intracoronary compared to intravenous abciximab in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention reduces mortality, target vessel revascularization and reinfarction after 1 year.
    Iversen AZ; Galatius S; Abildgaard U; Galloe A; Hansen PR; Pedersen S; Engstroem T; Jensen JS
    Cardiology; 2011; 120(1):43-9. PubMed ID: 22122887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intracoronary compared to intravenous bolus abciximab during primary percutaneous coronary intervention in ST-segment Elevation Myocardial Infarction (STEMI) patients reduces 30-day mortality and target vessel revascularization: a randomized trial.
    Iversen A; Abildgaard U; Galloe A; Hansen PR; Galatius S; Madsen JK; Engstroem T; Pedersen S; Jensen KS; Jensen JS
    J Interv Cardiol; 2011 Apr; 24(2):105-11. PubMed ID: 21175845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Does intracoronary abciximab improve the outcome of percutaneous coronary interventions? A randomized controlled trial].
    Galache Osuna JG; Sánchez-Rubio J; Calvo I; Diarte JA; Lukic A; Placer LJ
    Rev Esp Cardiol; 2006 Jun; 59(6):567-74. PubMed ID: 16790200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: a meta-analysis of randomized trials.
    Navarese EP; Kozinski M; Obonska K; Margheri M; Gurbel PA; Kubica J; De Luca G
    Platelets; 2012; 23(4):274-81. PubMed ID: 21988317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intracoronary versus intravenous abciximab bolus in patients with ST-segment elevation myocardial infarction: 1-year results of the randomized AIDA STEMI trial.
    Desch S; Wöhrle J; Hambrecht R; Rittger H; Birkemeyer R; Lauer B; Neuhaus P; Brosteanu O; Sick P; Pauschinger M; Kerber S; Kleinertz K; de Waha S; Eitel I; Schuler G; Thiele H
    J Am Coll Cardiol; 2013 Sep; 62(13):1214-5. PubMed ID: 23850911
    [No Abstract]   [Full Text] [Related]  

  • 26. Pooled Analysis Comparing the Efficacy of Intracoronary Versus Intravenous Abciximab in Smokers Versus Nonsmokers Undergoing Primary Percutaneous Coronary Revascularization for Acute ST-Elevation Myocardial Infarction.
    Piccolo R; Galasso G; Eitel I; Dominguez-Rodriguez A; Iversen AZ; Gu YL; Abreu-Gonzalez P; de Smet BJ; Esposito G; Windecker S; Thiele H; Piscione F
    Am J Cardiol; 2016 Dec; 118(12):1798-1804. PubMed ID: 27756477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intracoronary abciximab in diabetic patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Piccolo R; Eitel I; Galasso G; Iversen AZ; Gu YL; Dominguez-Rodriguez A; de Smet BJ; Mahmoud KD; Abreu-Gonzalez P; Thiele H; Piscione F
    Vascul Pharmacol; 2015 Oct; 73():32-7. PubMed ID: 26071862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial.
    Mehilli J; Kastrati A; Schulz S; Früngel S; Nekolla SG; Moshage W; Dotzer F; Huber K; Pache J; Dirschinger J; Seyfarth M; Martinoff S; Schwaiger M; Schömig A;
    Circulation; 2009 Apr; 119(14):1933-40. PubMed ID: 19332467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial.
    Stone GW; Maehara A; Witzenbichler B; Godlewski J; Parise H; Dambrink JH; Ochala A; Carlton TW; Cristea E; Wolff SD; Brener SJ; Chowdhary S; El-Omar M; Neunteufl T; Metzger DC; Karwoski T; Dizon JM; Mehran R; Gibson CM;
    JAMA; 2012 May; 307(17):1817-26. PubMed ID: 22447888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
    Garg S; Sarno G; Serruys PW; Rodriguez AE; Bolognese L; Anselmi M; De Cesare N; Colangelo S; Moreno R; Gambetti S; Monti M; Bristot L; Bressers M; Garcia-Garcia HM; Parrinello G; Campo G; Valgimigli M;
    JACC Cardiovasc Interv; 2011 Jan; 4(1):66-75. PubMed ID: 21251631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
    Valgimigli M; Campo G; Malagutti P; Anselmi M; Bolognese L; Ribichini F; Boccuzzi G; de Cesare N; Rodriguez AE; Russo F; Moreno R; Biondi-Zoccai G; Penzo C; Díaz Fernández JF; Parrinello G; Ferrari R
    JACC Cardiovasc Interv; 2011 Jan; 4(1):51-62. PubMed ID: 21251629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationale and design of the INFUSE-AMI study: A 2 × 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction.
    Gibson CM; Maehara A; Lansky AJ; Wohrle J; Stuckey T; Dave R; Cox D; Grines C; Dudek D; Steg G; Parise H; Wolff SD; Cristea E; Stone GW
    Am Heart J; 2011 Mar; 161(3):478-486.e7. PubMed ID: 21392601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of abciximab versus eptifibatide during percutaneous coronary intervention in ST-segment elevation myocardial infarction (from the HORIZONS-AMI trial).
    Singh HS; Dangas GD; Guagliumi G; Yu J; Witzenbichler B; Kornowski R; Grines C; Gersh B; Dudek D; Mehran R; Stone GW
    Am J Cardiol; 2012 Oct; 110(7):940-7. PubMed ID: 22748356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: results of the facilitated angioplasty with tirofiban or abciximab (FATA) in ST-elevation myocardial infarction trial.
    Marzocchi A; Manari A; Piovaccari G; Marrozzini C; Marra S; Magnavacchi P; Sangiorgio P; Marinucci L; Taglieri N; Gordini G; Binetti N; Guiducci V; Franco N; Reggiani ML; Saia F;
    Eur Heart J; 2008 Dec; 29(24):2972-80. PubMed ID: 18940887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved clinical outcomes with intracoronary compared to intravenous abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Hansen PR; Iversen A; Abdulla J
    J Invasive Cardiol; 2010 Jun; 22(6):278-82. PubMed ID: 20516508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ClearWayRX system to reduce intracoronary thrombus in patients with acute coronary syndromes according to optical coherence tomography after abciximab intracoronary local infusion trial (COCTAIL): study rationale and design.
    Capodanno D; Prati F; Pawlowsky T; Ramazzotti V; Albertucci J; La Manna A; Robert G; Tamburino C
    J Cardiovasc Med (Hagerstown); 2010 Feb; 11(2):130-6. PubMed ID: 19829141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial.
    Ndrepepa G; Kastrati A; Mehilli J; Neumann FJ; ten Berg J; Bruskina O; Dotzer F; Seyfarth M; Pache J; Dirschinger J; Berger PB; Schömig A
    Eur Heart J; 2008 Feb; 29(4):455-61. PubMed ID: 18158289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of intracoronary compared to intravenous abciximab administration in patients undergoing transradial percutaneous coronary intervention: A sub-analysis of the EASY trial.
    Bertrand OF; Rodés-Cabau J; Larose E; Nguyen CM; Déry JP; Proulx G; Roy L; Poirier P; Costerousse O; De Larochellière R
    Int J Cardiol; 2009 Aug; 136(2):165-70. PubMed ID: 18656274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).
    Akerblom A; James SK; Koutouzis M; Lagerqvist B; Stenestrand U; Svennblad B; Oldgren J
    J Am Coll Cardiol; 2010 Aug; 56(6):470-5. PubMed ID: 20670756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abciximab: a review and update for clinicians.
    Mazzaferri EL; Young JJ
    Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):609-18. PubMed ID: 18510478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.